DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder

Information source: University Hospital Case Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bipolar Disorder

Intervention: Lithium (Drug); Divalproex (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: University Hospital Case Medical Center

Official(s) and/or principal investigator(s):
Joseph R Calabrese, MD, Principal Investigator, Affiliation: Case Western Reserve University / University Hospitals of Cleveland


This study will determine the efficacy and safety of combination therapy with divalproex and lithium for treating mania in people with rapid cycling bipolar disorder and a substance abuse disorder.

Clinical Details

Official title: A Randomized, Double Blind Comparison of Lithium Monotherapy Versus Lithium Plus Divalproex for the Outpatient Management of Hypomania/Mania in Patients With Rapid Cycling Bipolar Disorder Comorbid With Substance Abuse/Dependence

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Time to Treatment for Emerging Symptoms of a Mood Relapse

Secondary outcome:

Time to Treatment for Emerging Symptoms of a Manic/Hypomanic/Mixed Episode

Time to Treatment for Emerging Symptoms of a Depressive Episode

Change in Rate of Alcohol Use Disorders After Open-label Treatment With Lithium and Divalproex

Change in Rate of Cannabis Use Disorders After Open-label Treatment With Lithium and Divalproex

Change in Rate of Cocaine Use Disorders After Open-label Treatment With Lithium and Divalproex

Detailed description: Longitudinal Evaluation of the Efficacy and Safety of Divalproex and Lithium in Dual Diagnosis Bipolar Rapid Cycling: This study recruits males and females age 18 and older who currently meet diagnostic criteria for rapid cycling bipolar disorder (type I or II) and who have met the criteria for substance abuse or dependence of cocaine, marijuana and/or alcohol within the past six months. Patients are initially stabilized on dual therapy of lithium and depakote and then randomly assigned to double-blind treatment with either lithium monotherapy or continued dual therapy. Patients remain in the study for six months or until they experience a relapse. Patients in this study are required to bring a friend or family member to all study visits as well as attend chemical dependency services. This study is sponsored by the NIMH. Subjects receive study-related care at no cost.


Minimum age: 16 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- To be included in this study, patients will be required to be either acutely

hypomanic or manic as defined by the Diagnostic and Statistical Manual - IV (DSM-IV)

and meet criteria for current substance abuse and/or dependence disorder within the last six months.

- Must have 4 or more episodes in the immediate 12 months prior to study entry.

- Males or females 16 - 65 years of age.

- A score of 60 or less on the Global Assessment Scale.

- Have no medical illness precluding the use of lithium or divalproex.

Exclusion Criteria:

- Patients who have had intolerable side effects to lithium levels 0. 8 meq/L or

divalproex levels of 50 ug/ml. Patients who have been completely non-responsive to lithium in the past will be excluded, whereas patients who have had partial responses to lithium will be permitted into the study.

- Patients with a prior history of seizure disorder, cerebral vascular disease,

structural brain damage from trauma, clinically significant focal neurological abnormalities, EEG abnormalities with frank paroxysmal activity or a previous CT/MRI scan of the brain with gross structural abnormalities.

- Patients who require anticoagulant drug therapy.

- Patients who have uncontrolled gastrointestinal, renal, hepatic, endocrine,

cardiovascular, pulmonary, immunological or hematological disease. Patients with alcohol-related liver disease as reflected by diffuse elevations in liver functions tests exceeding the upper limits of the normal range by 50% will be excluded.

- Patients who are pregnant or plan to become pregnant during the study.

- Patients who have received haloperidol decanoate or fluphenazine decanoate within the

last 10 weeks.

- Patients who have a central nervous system (CNS) neoplasm, uncontrolled metabolic,

demyelinating or progressive disorder; active CNS infection; or any progressive neurological disorder.

- Patients who are taking exogenous steroids.

- Patients who do not meet criteria for substance abuse or dependence.

Locations and Contacts

University Hospitals of Cleveland, Cleveland, Ohio 44106, United States
Additional Information

Starting date: November 1997
Last updated: November 4, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017